INTELLECTUAL PROPERTY

Intellectual Property

BIND has built the premier intellectual property portfolio in the targeted nanoparticle field. Through a combination of in-licensing core technology intellectual property and inventing processes and compositions necessary for the successful commercialization of targeted nanoparticles, BIND has positioned itself to successfully advance important therapeutics to market while maintaining a market dominant intellectual property position.

BIND has licensed many field advancing inventions from prominent institutions such as Massachusetts Institute of Technology, Harvard Medical School, Brigham & Women’s Hospital, and Johns Hopkins University. Building on these important and critical advances in nanomedicine, BIND has applied the rigor and experience of talented pharmaceutical development professionals to develop targeted nanoparticle therapeutics which can be successfully commercialized and acceptable to regulatory authorities. BIND’s Medicinal Nanoengineering™ platform encompasses key advances, including development of long circulating nanoparticles that comprise FDA-approved excipients and can be optimized in a combinatorial fashion to efficiently target diseased tissues and cell types. Each of these BIND licensed and BIND invented critical advances is protected by numerous BIND-licensed or BIND-owned patents, patent applications and trade secrets.

BIND has over 50 different patent families consisting of US patents, US patent applications and international applications.

Each patent family covers a key aspect of targeted nanoparticle technology including specific product compositions or components such as proprietary polymers and targeting ligands, nanoparticle manufacturing methods, and critical nanoparticle attributes such as drug release kinetics, tissue and cell trafficking and long circulation times. In addition to BIND’s patent portfolio, BIND has retained a number of trade secrets around large scale manufacturing of targeted nanoparticles and identification of optimal properties for targeted nanoparticle selection.

BIND’s Medicinal Nanoengineering™ Platform produces products with very strong and long market exclusivity profiles. By presenting a combination of patent, regulatory, and scientific barriers to generic drug competition, BIND targeted nanoparticle products will enjoy significant exclusivity terms covering the full patent protection period and potentially beyond.

BIND’s targeted nanoparticles provide better market exclusivity than typical formulations, new chemical entities, peptides and proteins. Click the below link to access BIND’s article in Nature Biotechnology describing how the combination of patent, regulatory, and scientific barriers to generic competition create a long market exclusivity profile

In addition to building a patent portfolio around specific products, BIND is establishing a patent position around critical properties and techniques necessary to develop and commercialize successful targeted nanotherapeutics. BIND is investing scientific and patent resources in identifying these critical properties and techniques so that BIND can maintain the premier intellectual property portfolio in the targeted nanoparticle field. This resource investment has resulted in a number of critical inventions and patent filings supporting BIND’s platform.

• Therapeutic nanoparticle product compositions
• Classes of therapeutic nanoparticle compositions
• Methods of using therapeutic nanoparticles
• Methods of manufacturing therapeutic nanoparticles
• Critical nanoparticle components (e.g., polymers and targeting ligands)
• Nanoparticle pharmacokinetic and biodistribution profiles
• Drug release profilesNovel targets and targeting strategies